Sep 10, 2019 / 02:35PM GMT
David Reed Risinger - Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
Let's get started here. So thanks, everyone, for joining us for this session with Bausch Health. It's very much my pleasure to welcome Paul Herendeen, who was the company's CFO. And I just need to refer you to disclaimers at www.morganstanley.com/researchdisclosures.
And I thought that it makes sense to ask Paul to offer some brief opening remarks about the company's transformation, and then we'll go into Q&A.
So Paul, thank you again for being here.
Paul S. Herendeen - Bausch Health Companies Inc. - Executive VP & CFO
Yes, thanks, David. And it's great to be here. I'll give you a friendly opening remarks by saying, when Joe joined in the beginning of '16, and then I joined in the summer of '16, this was the first conference that I came to in 2016 as then the CFO of Valeant. And I just can't tell you how different it is sitting
Bausch Health Companies Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers